SOPHARMA AD: Current report 62 extab ENG

opublikowano: 2013-05-13 15:18

Spis treści:

1. REPORT

2. INFORMATION ABOUT THE ENTITY

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY


Spis załączników:
Current_report_62_extab_ENG.doc  (REPORT)

POLISH FINANCIAL SUPERVISION AUTHORITY
UNI - EN REPORT No 62 / 2013
Date of issue: 2013-05-13
Short name of the issuer
SOPHARMA AD
Subject
Current report 62 extab ENG
Official market - legal basis
Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne
Unofficial market - legal basis
Contents of the report:

Pursuant to art.100k, par.1 of POSA we hereby notify, that the Board of Directors of Sopharma AD authorized the Executive Director to begin negotiations for the sale of all shares representing 85% of the capital of the subsidiary Extab Corporation, owned by Sopharma AD. The negotiations will be conducted as part of the strategy for development of the original products of Sopharma AD on new markets, on which the Company does not possess the necessary resources for such actions in the near future.
Annexes
File Description
Current report 62 extab ENG.docCurrent report 62 extab ENG.doc Current report 62 extab ENG

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2013-05-13 Ognian Donev Executive director